Genzyme Makes Senior Appointments

Date: March 5, 2008

Simon Cousins appointed Vice-President, Contract Manufacturing Organisations and Dominic Carolan appointed Senior Vice President, both Haverhill and Waterford Operations

Genzyme, a global leader in biotechnology, announces the appointment of Dominic Carolan as Senior Vice-President, for the Haverhill, UK and Waterford, Ireland operations and Simon Cousins as Vice-President, Contract Manufacturing Organisations. Both will be based at the Haverhill facility.

Dominic Carolan, who has been promoted to SVP, with responsibility for both Haverhill and Waterford Operations, was previously at the Waterford facility where he built up the organisation and operational competencies of the site. The alignment of the Haverhill and Waterford sites under Dominic’s leadership will allow the organisation to continue to grow these two sites to serve Genzyme’s patient needs. Previous to working at Genzyme Dominic was Managing Director at Tyco Healthcare Ireland.

In the last eleven years, Simon Cousins has led the development of Genzyme’s Haverhill operations with major investments in bulk Renagel/Renvela manufacture, breakthroughs in process R&D and significant growth of the label, pack and distribution operation. Prior to Genzyme Simon held roles at Hoechst Pharmaceuticals. In his new role Simon will be responsible for assessing the use of contract manufacturing organisations (CMOs) and developing Genzyme’s plans for CMOs as part of the Company’s long term supply strategies, and will also be involved in supporting acquisitions with a global responsibility. Simon will be reporting to Jim Shuman, SVP Materials Management.

Mark Bamforth, Senior Vice President, Corporate Operations & Pharmaceuticals said; “Both Simon and Dominic have played crucial roles in the growth of our UK and Ireland businesses and I am delighted to have people of their calibre on board. It is a testament to strength of Genzyme’s employees that we are able to fill these two positions from within the organisation. I look forward to their continued contributions in driving our business forward and developing innovative therapies for patients around the world.”

Dominic Carolan, said; “Clearly, there are challenges ahead in our current climate, but I am encouraged that the continued good performance of the company is a testament not only to the core values that guide our actions and the longstanding excellence of service to patients but also to the quality of Genzyme’s employees in the UK and Ireland.”

Simon Cousins added; “I have immensely enjoyed my time leading the Haverhill facility and working with the hugely talented teams there. This promotion is a great opportunity for me, not only as it allows me to progress with my professional career but also because it allows me to do so while remaining at Genzyme – a company I believe is united by its commitment to people with serious diseases and has the dedication and entrepreneurialism to continue to make major positive impacts on the lives of these patients.”

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme in the UK

Genzyme in the UK employs 600 people in research, development as well as commercial manufacturing and distribution roles. Genzyme UK comprises four different sites; Oxford, Kent, Haverhill and Cambridge.

Genzyme Therapeutics operates from the Oxford office and markets products for the treatment of patients with chronically debilitating diseases, like genetic disorders, such as lysosomal storage disorders (LSDs).

Genzyme Diagnostics UK is based on two sites at West Malling and Allington, near to Maidstone in Kent. Genzyme Diagnostics UK includes a Sales and Marketing group, Manufacturing Operations and a Research and Development Team.

Genzyme Haverhill Operations is located on the Cambridgeshire Suffolk border. The site has been a part of Genzyme since 1982, employs 350 people and has three distinct functions: cold chain supply centre, manufactures APIs and scale up and development of Genzyme’s new synthetic molecules.

Genzyme Europe Research is Genzyme’s first dedicated R&D facility in Europe. The science team is currently focused on Antibody Technology.

Terms and Conditions of Use | Privacy Policy | © 2003-2010 Genzyme Corporation. All rights reserved.